opportunity for 500% increase

EIF in conjuction with www.map.com.
Map pharmecueticals ,will be conducting human trials
regarding inhaled insulin and an improved asthma delivery system using eiffeltechnology nano particles.
map pharmecueticals have recieved a US 25 Million dollars grant.
Also inhaled insulin has been approved in Europe, matter of time that EIF AND MAP capture the US market.
At these prices excellent entry point.One to put on
your watch list.
Have been involved with EIF for along time.